Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | GLP1R | P43220 | 8/20 | 0.42 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29548162 | 0.94 | GLP1R (0.48) | HPGDSMN1; SMN2HTTGLP1RNOD1 | |
| SCHEMBL22389098 | 0.84 | ALB (0.47) | GLP1RNOD1FOLH1 | |
| SCHEMBL23964077 | 0.84 | HPGD (0.48) | HPGDSMN1; SMN2HTTTP53ALDH1A1 | |
| SCHEMBL25682604 | 0.84 | GLP1R (0.49) | HPGDSMN1; SMN2HTTGLP1RNOD1 | |
| SCHEMBL22223503 | 0.83 | GLP1R (0.52) | HPGDSMN1; SMN2HTTGLP1RNOD1 | |
| SCHEMBL30410719 | 0.83 | GLP1R (0.51) | HPGDSMN1; SMN2HTTGLP1RNOD1 | |
| SCHEMBL25331009 | 0.83 | GLP1R (0.50) | HPGDSMN1; SMN2HTTGLP1R | |
| SCHEMBL25331006 | 0.83 | GLP1R (0.50) | HPGDSMN1; SMN2HTTGLP1R | |
| SCHEMBL24983125 | 0.83 | NOD1 (0.47) | NOD1ALDH1A1MEN1KMT2AFOLH1 | |
| SCHEMBL25332373 | 0.82 | GLP1R (0.47) | HPGDSMN1; SMN2HTTGLP1RTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230025327-A1 | CONJUGATES OF TUBULYSIN DERIVATIVES AND CELL BINDING MOLECULES AND METHODS OF MAKING | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-01-26 | — | — | US | disclosed |
| EP-3991752-A1 | CELL-BINDING MOLECULE-TUBULYSIN DERIVATIVE CONJUGATE AND PREPARATION METHOD THEREFOR | Hangzhou Dac Biotech Co., Ltd (CN) | 2022-05-04 | — | — | EP | disclosed |
| WO-2021000067-A1 | CELL-BINDING MOLECULE-TUBULYSIN DERIVATIVE CONJUGATE AND PREPARATION METHOD THEREFOR | 杭州多禧生物科技有限公司 | 2021-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230025327-A1 | CONJUGATES OF TUBULYSIN DERIVATIVES AND CELL BINDING MOLECULES AND METHODS OF MAKING | TEK, TEKT1, EPCAM | HPGD 4601/4885SMN1; SMN2 3373/4885HTT 3233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.